Metrics raised 2
- FY27 revenue growth guide raised to 14-16% (from 12-13%)
- FY27 consolidated EBITDA margin guide raised to ~23% (from 22%)
Event Participants
Executives
2 Ajit Kumar Jain, Harish Kramat
Analysts
10 Aditya Chheda, Ankeet Pandya, Kartik Bane, Kunal Randeria, Mohit Vijay, Nitin Agarwal, Rashad (Motilal), Rashmi Shetty, Saion Mukherjee, Shilpa Saboo
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹2,788 crore | +21% YoY vs ₹2,309 crore; rupee depreciation contributed ~5 pts of growth |
| Domestic Formulation Revenue | ₹1,082 crore | +13% YoY vs ₹961 crore; chronic +17.2%, acute +8.9%, both ahead of IPM |
| Export Revenue | ₹603 crore | +34% YoY vs ₹450 crore; generic excl. tender +27%, institutional +107%, branded ROW +16% |
| API Business Revenue | ₹424 crore | +30% YoY vs ₹362 crore |
| Institutional Revenue | ₹111.75 crore | +107% YoY vs ₹58 crore; ~₹40 crore of March shipments shifted to April (one-off timing) |
| Generic Business Revenue (excl. tender) | ₹340 crore | +27% YoY vs ₹268 crore; UK/Europe +70% to ₹137 crore |
| Consolidated EBITDA | ₹638 crore | +50% YoY vs ₹425 crore |
| Consolidated EBITDA Margin | 22.88% | +449 bps YoY (18.39%); driven by personal cost (-1.95% of sales) and mfg cost (-1.19% of sales) |
| Standalone EBITDA Margin | 26% | Up from 23.82% in Q1 FY26; absolute EBITDA +~34% YoY |
| Market Share (India, IQVIA) | 2.08% | +1 bps vs 2.07% in mid-March 2026; rank ~20 (May-June '26) |
| Gross Debt | ₹193 crore | Zero working capital debt; ~$50 mn USD loans fully repaid before March |
Geographic & Segment Commentary
India Formulations: Revenue +13% YoY to ₹1,082 crore; outperformed IPM in both chronic (+17.2% vs 15.2% market) and acute (+8.9% vs ~5% IPM) segments; market share improved to 2.08%; top 6 brands in India's top 300 brands; segment growth — pain management +13%, CV/anti-diabetic +17%, CNS +19%, derma +17%, urology +25%, ophthalmology +17%; malaria declined 24% but is now ~1% of business.
Europe/UK: Generic business grew ~70% to ₹137 crore (from ₹83 crore), the main driver of generic growth; new product launches supportive; margin profile improving.
US: Shipments up 8% YoY; Unichem's US business grew 27% (Unichem's own portfolio +9%, IPCA portfolio sold via Unichem +37%); API source-change filings with FDA ongoing for IPCA supply.
ROW & Promotional Markets: Grew 16% to ₹143 crore (from ₹124 crore); field force and non-trading offices in international markets expanding.
Institutional Business: Grew 107% to ₹111.75 crore but ~₹40 crore of March shipments shifted to April due to shipping delays; management expects single-digit normalized growth (₹260-300 crore range).
API Business: Grew ~30% to ₹424 crore (from ₹362 crore); new plants at Devas and Wardha addressing capacity constraints at Ratlam.
Unichem (Subsidiary): Brazil +52% (turning profitable), Europe +3%, Acacia/ROW doubled from ₹8 crore to ₹17 crore, API +73% to ₹58 crore; margin improvements driven by captive API production, European profitability and Brazil turnaround; US margins remain under pressure.
Company-Specific & Strategic Commentary
Domestic Market Share Gains: IQVIA market share improved to 2.08% (vs 2.07% in March 2026); maintained top-20 rank (May-June '26); chronic segment growing faster than market (17.2% vs 15.2%); domestic volume growth ~5%, price ~4.5-5%, new launches ~2%.
Field Force Expansion: ~7,000 medical reps; expansion largely complete; ~200 additional reps to be added mid-FY27 for new divisions.
Biosimilars: 7 candidates in pipeline; 2 products in engineering batches/validation with results in line with expectations; Phase 3 trials exempt from RLD requirement by EU and US regulators; clinical trials expected to start next fiscal; revenue visibility from FY29-FY30; ~₹100 crore additional biotech investment this year including piloting facilities.
Capex Plans: ₹700-800 crore in FY27 across controlled-release formulations at Ratlam, new API plants at Devas and Wardha (intermediates), continuous process conversion, and biotech R&D assets.
Balance Sheet Strength: ~$50 mn USD loans fully repaid before March, eliminating currency risk; gross debt ₹193 crore (long-term only); zero working capital debt; net cash positive; ₹70 crore term loan at low rates retained until maturity.
US & Global Filings: 4-5 new US filings per year (IPCA); Unichem has a dedicated filing program for Europe, Australia, New Zealand, Canada and Chile (approval timeline ~1.5 years); combined US launches ~7-8 per year.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | 14-16% (revised from 12-13%) | Upside driven by generic business (UK/Europe +70%), India (+13%) and API (+30%) |
| FY27 Consolidated EBITDA Margin | ~23% (revised from 22%) | Cost ratios improving; rupee depreciation benefit partially offset by dollar-denominated costs |
| India Business Growth | 12-13% (maintained) | Chronic growth strong (17.2%); market growth improving |
| Institutional Business | ₹260-300 crore, single-digit growth | Normalized after ₹40 crore one-off timing benefit |
| US Business Growth | 15-17% possible | Depends on 7-8 launches/year and source-change approvals |
| Unichem (Revenue / EBITDA Margin) | 10% / 13% (not yet revised) | Want more quarters of performance before revisiting |
| Medium-term Standalone EBITDA Margin | ~30% (2-3 years) | From current ~26% |
| Medium-term Consolidated EBITDA Margin | 25-26% (2-3 years) | Subsidiaries improving incl. Unichem |
| FY28 Guidance | To be provided at Q4 FY27 | — |
Risks & Constraints
| Risk | Context |
|---|---|
| Freight & logistics cost inflation | Container rates up to 3x on South American routes ($3,000→$9,000-10,000), US containers $7,000-7,500→$12,500-13,000, Europe $3,000→$5,500; availability remains difficult; management sees no margin pressure but costs are baked into FY27 views |
| Raw material price volatility | Petroleum price-driven fluctuations and supply chain disturbances; material cost ~25% of sales; management expects material cost to decline relative to sales over the year |
| Rupee depreciation | Dual impact — boosts revenue realizations but raises dollar-denominated costs (material, freight, international field force salaries, testing equipment, imported machines and maintenance contracts) |
| Shipping delays | Institutional business timing affected (₹40 crore shift from March to April); nominated shipments cause unpredictable quarterly phasing |
| Malaria segment decline | -24% YoY in Q1 FY27; now ~1% of overall business; drags acute segment growth |
| Unichem margin pressure | US market remains price-competitive; margin recovery depends on product mix, captive API supply and new market entries (Europe, Australia, NZ, Canada, Chile); guidance kept under review |
| Biosimilar investment risk | ~₹100 crore+ annual investment; no revenues for ~2 years; clinical trial and approval execution risks across global markets |
Q&A Highlights
India Business & Segment Performance
- Question: What's driving the acute segment performance and the overall India outlook? (Rashmi Shetty, Dolat Capital)
- Answer: Outperformed IPM in both chronic (+17.2% vs 15.2% market) and acute (+8.9% vs ~5% market); malaria dragged acute (-24%) but now just ~1% of business; pain management +13%, CV/anti-diabetic +17%, CNS +19%, urology +25%, ophthalmology +17%; India growth guidance of 12-13% retained (Ajit Kumar Jain)
Institutional Business Normalization
- Question: What is normalized institutional growth? (Rashmi Shetty, Dolat Capital)
- Answer: ₹40 crore of March shipments moved to April due to shipping delays and nominated shipment timing; single-digit growth expected; business range of ₹260-300 crore; not targeting high growth (Ajit Kumar Jain)
Generic/EU Growth & Guidance Upgrade
- Question: Are UK supply issues resolved, and will generic guidance be upgraded? (Rashmi Shetty, Dolat Capital)
- Answer: UK/Europe +70% to ₹137 crore (from ₹83 crore); US shipments +8%; Canada slightly lower; generic excl. institutions rose from ₹268 crore to ₹370 crore; FY27 revenue growth guidance revised from 12-13% to 14-16% (Ajit Kumar Jain)
Unichem Performance
- Question: Where does Unichem stand on growth and margins? (Rashmi Shetty, Dolat Capital)
- Answer: Unichem US +27% (own portfolio +9%, IPCA portfolio via Unichem +37%); Brazil +52% and turning positive; Europe +3%; Acacia doubled to ₹17 crore; API +73% to ₹58 crore; Unichem guidance (10% growth, 13% margin) not revisited — want more quarters of performance (Ajit Kumar Jain)
US Business Outlook
- Question: Expected US launches and growth trajectory? (Kunal Randeria, Axis Capital)
- Answer: 7-8 launches per year combined (3-4 each from IPCA and Unichem); API source-change approvals partially received, some on CB30/fast-track; US growth of ~15-17% possible (Ajit Kumar Jain)
Material Costs, Freight & Margin Outlook
- Question: What's the quantum of material cost impact in coming quarters? (Kunal Randeria, Axis Capital)
- Answer: Freight rates tripled on some routes (South America $3,000→$9,000-10,000; US $7,000-7,500→$12,500-13,000; Europe $3,000→$5,500); margin improvement came from personal cost (-1.41% of sales) and manufacturing cost (-0.91%), not material savings (only 0.14%); no margin pressure expected — material cost will decline relative to sales (Ajit Kumar Jain)
EBITDA Margin Guidance & Rupee Impact
- Question: Revised EBITDA margin guidance for FY27? (Rashad, Motilal)
- Answer: Consolidated guidance revised from 22% to ~23% for FY27; rupee depreciation benefits partially offset by dollar-denominated costs — material (25% of sales), freight, international field force salaries, testing equipment and maintenance; prices are being increased, not renegotiated down (Ajit Kumar Jain)
Capex & Capital Deployment
- Question: How will incremental cash flows be deployed — acquisitions or capacity? (Kartik Bane, Bajaj Allianz Life)
- Answer: ₹700-800 crore capex in FY27: Ratlam controlled-release capacity, Devas API plant, Wardha intermediates, continuous process conversion, biotech piloting; no acquisitions on the table (Ajit Kumar Jain)
Debt & Interest Cost
- Question: Reason for interest cost decline? (Rashmi Shetty, Dolat Capital)
- Answer: $50 mn USD loans fully repaid before depreciation began; gross debt ₹193 crore; zero working capital debt; ₹70 crore term loan at cheap rates retained until maturity; net earning position now (Ajit Kumar Jain)
Biosimilars Pipeline
- Question: Biosimilar candidates, timeline and investment? (Saion Mukherjee, Nomura)
- Answer: 7 candidates; 2 in engineering batches/validation with in-line results; Phase 3 exempt from RLD requirement in EU/US; clinical trials start next fiscal; revenue from FY29-30; ~₹100 crore additional annual investment; targeting all global markets (Ajit Kumar Jain)
Key Takeaway
IPCA Laboratories delivered strong Q1 FY27 results with consolidated revenue up 21% to ₹2,788 crore and EBITDA margin expanding 449 bps to 22.88% (₹638 crore), driven by broad-based growth — India formulations +13% to ₹1,082 crore, exports +34% to ₹603 crore, API +30% to ₹424 crore — and better cost ratios (personal and manufacturing costs down ~1.95% and ~1.19% of sales respectively); domestic market share improved to 2.08% with chronic growth at 17.2% vs market 15.2%. Management upgraded FY27 revenue guidance from 12-13% to 14-16% and consolidated EBITDA margin guidance from 22% to ~23%, with upside led by generics (UK/Europe +70%) and India; institutional growth (+107% to ₹111.75 crore) includes ₹40 crore of pulled-forward shipments, with normalized single-digit growth of ₹260-300 crore expected. Strategy centers on biosimilars (7 candidates, ~₹100 crore incremental annual spend, revenue from FY29-30), ₹700-800 crore capex for controlled-release formulations and API plants, and a near-debt-free balance sheet (₹193 crore gross debt, zero working capital debt). Watch items include freight cost inflation (up to 3x on key routes) and Unichem's margin trajectory; FY28 guidance deferred to Q4 FY27.